Lenvatinib in the therapy of thyroid cancer:A single institutional experience
-
- YAMAUCHI Moriyasu
- Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
-
- MINESAKI Akimichi
- Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
-
- SATO Yuki
- Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
-
- KURATOMI Yuichiro
- Department of Otolaryngology-Head & Neck Surgery, Saga University Faculty of Medicine
Bibliographic Information
- Other Title
-
- 当科における甲状腺癌に対するレンバチニブ治療経験
Search this article
Description
<p>We retrospectively reviewed the safety and efficacy of treatment with lenvatinib for thyroid cancer. Eight patients with thyroid cancer (five with papillary carcinoma, two with medullary carcinoma, and one with squamous cell carcinoma) were analyzed. Five patients were male, and three were female. The median age was 67.8 years. Five patients were treated for recurrent disease after definitive therapy, and three were treated as primary therapy for metastatic or unresectable disease. The median overall survival was 12.9 months. The best objective responses were a partial response for six cases, stable disease for one case, and progressive disease for one case. The response rate was 75%. Common adverse events were as follows:hypertension, fatigue, palmar-plantar erythrodysesthesia syndrome, diarrhea, nausea/vomiting, and decreased platelet count. All patients experienced drug withdrawal and dose reduction. All but one patients achieved disease control at three months. At 12 months, a long-term response had been achieved by 5 patients. A rare case of thyroid squamous cell carcinoma is described.</p>
Journal
-
- jibi to rinsho
-
jibi to rinsho 64 (6), 228-236, 2018-11-20
JIBI TO RINSHO KAI
- Tweet
Details 詳細情報について
-
- CRID
- 1390001277380711168
-
- NII Article ID
- 130007740524
-
- ISSN
- 21851034
- 04477227
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed